Medical Facilities Valuation
Is 31F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 31F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 31F (€10.4) is trading below our estimate of fair value (€112.49)
Significantly Below Fair Value: 31F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 31F?
Key metric: As 31F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 31F's PE Ratio? | |
|---|---|
| PE Ratio | 13.3x |
| Earnings | US$19.53m |
| Market Cap | US$261.54m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 4.4x |
| PEG Ratio | -0.4x |
Price to Earnings Ratio vs Peers
How does 31F's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.7x | ||
M12 M1 Kliniken | 17.9x | 17.5% | €300.6m |
RHK RHÖN-KLINIKUM | 18.9x | 7.5% | €850.1m |
LIK LIMES Schlosskliniken | 22.9x | n/a | €98.5m |
JTH Gesundheitswelt Chiemgau | 7x | n/a | €24.4m |
31F Medical Facilities | 13.3x | -30.0% | €365.3m |
Price-To-Earnings vs Peers: 31F is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (16.7x).
Price to Earnings Ratio vs Industry
How does 31F's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 31F is good value based on its Price-To-Earnings Ratio (13.3x) compared to the European Healthcare industry average (18.2x).
Price to Earnings Ratio vs Fair Ratio
What is 31F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 13.3x |
| Fair PE Ratio | 8.2x |
Price-To-Earnings vs Fair Ratio: 31F is expensive based on its Price-To-Earnings Ratio (13.3x) compared to the estimated Fair Price-To-Earnings Ratio (8.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €10.40 | €10.99 +5.7% | 4.4% | €11.47 | €10.51 | n/a | 2 |
| Nov ’25 | €9.50 | €9.78 +3.0% | 5.1% | €10.28 | €9.29 | n/a | 2 |
| Oct ’25 | €8.90 | €9.78 +9.9% | 5.1% | €10.28 | €9.29 | n/a | 2 |
| Sep ’25 | €9.20 | €9.78 +6.3% | 5.1% | €10.28 | €9.29 | n/a | 2 |
| Aug ’25 | €9.50 | €9.49 -0.1% | 7.1% | €10.17 | €8.81 | n/a | 2 |
| Jul ’25 | €8.45 | €9.49 +12.3% | 7.1% | €10.17 | €8.81 | n/a | 2 |
| Jun ’25 | €8.45 | €9.49 +12.3% | 7.1% | €10.17 | €8.81 | n/a | 2 |
| May ’25 | €7.80 | €7.47 -4.2% | 9.1% | €8.15 | €6.79 | n/a | 2 |
| Apr ’25 | €7.25 | €7.47 +3.0% | 9.1% | €8.15 | €6.79 | n/a | 2 |
| Mar ’25 | €6.90 | €6.87 -0.4% | 8.9% | €7.48 | €6.26 | n/a | 2 |
| Feb ’25 | €6.30 | €6.87 +9.0% | 8.9% | €7.48 | €6.26 | n/a | 2 |
| Jan ’25 | €6.10 | €6.87 +12.6% | 8.9% | €7.48 | €6.26 | n/a | 2 |
| Dec ’24 | €6.10 | €6.87 +12.6% | 8.9% | €7.48 | €6.26 | n/a | 2 |
| Nov ’24 | €6.15 | €7.15 +16.2% | 8.8% | €7.77 | €6.52 | €9.50 | 2 |
| Oct ’24 | €6.50 | €6.86 +5.6% | 7.2% | €7.50 | €6.29 | €8.90 | 3 |
| Sep ’24 | €6.25 | €6.86 +9.8% | 7.2% | €7.50 | €6.29 | €9.20 | 3 |
| Aug ’24 | €5.85 | €6.62 +13.1% | 4.0% | €6.85 | €6.25 | €9.50 | 3 |
| Jul ’24 | €5.60 | €6.86 +22.4% | 6.7% | €7.56 | €6.28 | €8.45 | 4 |
| Jun ’24 | €5.60 | €6.86 +22.4% | 6.7% | €7.56 | €6.28 | €8.45 | 4 |
| May ’24 | €5.60 | €6.72 +19.9% | 7.5% | €7.49 | €6.09 | €7.80 | 4 |
| Apr ’24 | €5.30 | €6.93 +30.7% | 7.6% | €7.76 | €6.31 | €7.25 | 4 |
| Mar ’24 | €5.80 | €6.87 +18.4% | 6.2% | €7.52 | €6.33 | €6.90 | 4 |
| Feb ’24 | €5.40 | €6.87 +27.2% | 6.2% | €7.52 | €6.33 | €6.30 | 4 |
| Jan ’24 | €5.30 | €7.15 +34.9% | 5.8% | €7.78 | €6.61 | €6.10 | 4 |
| Dec ’23 | €5.60 | €7.15 +27.7% | 5.8% | €7.78 | €6.61 | €6.10 | 4 |
| Nov ’23 | €8.00 | €8.63 +7.9% | 5.4% | €9.26 | €8.12 | €6.15 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.54
7D
-1.8%
1Y
-37.1%
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.18
7D
-2.7%
1Y
6.1%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.8%
1Y
15.7%